Safety and Efficacy Study Comparing ETS6103 With Amitriptyline in the Treatment of Major Depressive Disorder (MDD)
Status:
Completed
Trial end date:
2015-10-01
Target enrollment:
Participant gender:
Summary
To demonstrate that the antidepressant activity of ETS6103 is not inferior to amitriptyline
in subjects who have an unsatisfactory response to / are resistant to treatment with SSRIs.
Phase:
Phase 2
Details
Lead Sponsor:
e-Therapeutics PLC
Treatments:
Amitriptyline Amitriptyline, perphenazine drug combination Serotonin Uptake Inhibitors